FDA Fast Tracks Enolen For Localized Prostate Cancer Treatment

The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alessa Therapeutics for its lead product candidate, Enolen, to expedite the development of a localized treatment for patients with low to intermediate risk prostate cancer.

This designation is intended for drugs that treat serious conditions and show the potential to fill unmet medical needs, allowing for more frequent communication with the FDA and a rolling review of marketing applications. By focusing on localized drug delivery, the clinical-stage biopharmaceutical company aims to provide patients with early-stage disease with an alternative to active surveillance or aggressive treatments that often carry significant lifestyle and health consequences, according to a news release issued by the company.

The development of Enolen is driven by the need for therapies that address the disease while reducing the physical and mental burden placed on patients.

“Receiving Fast Track designation for Enolen is further evidence of the urgent need for new treatment options for early-stage prostate cancer. Patients living with prostate cancer deserve an alternative to active surveillance or being faced with the considerable negative side effects common with the more aggressive treatment options available today,” said Cam Gallagher, president and CEO of Alessa Therapeutics, in a statement included in the news release. “We will continue to collaborate closely with the FDA to advance a new treatment option for men suffering not only from the disease itself, but who often face a heavy burden in deciding between not treating their cancer or pursuing therapies with significant health and lifestyle consequences.”

The localized delivery technology is designed to deliver anti-androgens directly to the diseased tissue within the prostate. By targeting the medication to the specific site of the cancer, the technology seeks to achieve high local drug concentrations that are effective against the disease.

Data from preclinical and clinical studies conducted to date indicate that the implant technology used in Enolen can provide a durable and continuous release of anti-cancer agents. These findings support the potential for the treatment to maintain effective drug levels at the site of the tumor over a sustained period. This localized approach is intended to leverage the effectiveness of Xtandi (enzalutamide), an FDA-approved prostate cancer compound, without the issues associated with systemic exposure. The goal of the technology is to ensure that the medication remains concentrated where it is needed most, rather than circulating throughout the entire body, which is the primary method of delivery for traditional anti-androgen and testosterone-lowering drugs.

Enolen is currently being evaluated in a phase 1 clinical trial. This study is designed to assess the safety, tolerability and preliminary efficacy of the localized sustained delivery of Xtandi into the prostate. Researchers are monitoring how well patients tolerate the implants and whether the drug is delivered effectively to the targeted tissue. Alessa Therapeutics has stated that it expects to present the initial findings from this phase 1 study this year. This trial represents a critical step in determining if the localized delivery system can meet the clinical requirements for treating patients with low-to-intermediate risk localized prostate cancer who are seeking alternatives to the current standard of care.

The safety profile of Enolen is a primary focus of its development, as the localized delivery method is specifically designed to minimize the potential negative side effects resulting from systemic exposure to medication. Traditional systemic anti-androgen and testosterone-lowering drugs are associated with a range of side effects that can impact a patient's quality of life, including sexual dysfunction, loss of muscle mass, cognitive issues, metabolic syndrome and cardiovascular events. By delivering the medication directly to the prostate, Enolen aims to eliminate these systemic complications. The ongoing phase 1 trial will continue to gather data on the tolerability of the treatment to ensure that the high local drug concentrations do not cause adverse effects while successfully avoiding the risks linked to traditional whole-body hormone therapies.

Reference

1. “Alessa Therapeutics Announces FDA Fast Track Designation for Enolen, A First-Of-Its-Kind Treatment for Localized Prostate Cancer,” news release; https://alessatherapeutics.com/news/alessa-therapeutics-announces-fda-fast-track-designation-for-enolen-a-first-of-its-kind-treatment-for-localized-prostate-cancer/

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.